NNVC

NanoViricides is a self-described "development stage company that has no products approved for commercial sale, never generated any revenues and may never achieve revenues or profitability." That is not analyst framing — it is the company's own Risk Factors language, and the numbers confirm it: revenue has been $0.00 across FY2021–FY2025 while net losses have run between -$8.1M and -$9.47M every year, with the FY2025 loss actually widening 14.1% YoY. There is no top line to grow into, no margin trend to reward, and an accumulated deficit of -$149M. Return on equity of -125.9% is a mechanical artifact of burning capital with no offsetting income.

The balance sheet is the disqualifier. Cash fell 67.5% to just $1.56M and current assets dropped 66.4% to $1.67M, while operating cash flow was -$8.48M (itself worsening 34.3%). That pace of burn against $1.56M of cash implies only a couple of months of runway — the filing states plainly the Company "will need to raise substantial additional capital" and "will be unable to proceed with its business plan without obtaining additional financing." Shares outstanding already grew 18.8% in a year to 17.4M; near-term survival almost certainly requires further dilutive equity issuance at a depressed ~$1.33 penny-stock price, directly transferring value away from existing holders. Total equity itself shrank 34.4% to $7.52M. The low 0.17x liabilities/equity ratio is the only clean line here, but a light debt load is cold comfort when the equity base is evaporating.